Tilray Brands Posts Record Fiscal 2026 Revenue $915.5M, Adjusted EBITDA $61.1M
Tilray Brands (TLRY) reported fiscal 2026 net revenue of $915.5M, up 11% from $821.3M, and record adjusted EBITDA of $61.1M, up from $55.0M. Gross profit rose to $260.4M. The company posted a $105.2M net loss mainly from non-cash charges, ended with about $235M cash and marketable securities, and guided fiscal 2027 adjusted EBITDA of $68–$75M.
How this was made
The 30-second read
Why it matters
The combination of record fiscal 2026 revenue/EBITDA, improved operating cash flow (excluding working capital), and explicit fiscal 2027 adjusted EBITDA guidance creates a clear near-term valuation catalyst, though the reported net loss underscores accounting and non-cash charge risk.
Market read
This is a primary financial results and guidance update that can reset expectations for adjusted profitability and cash generation into fiscal 2027.
What to watch
The article emphasizes adjusted metrics; traders may discount the quality of earnings without more detail on working-capital dynamics, capex needs, and the durability of the beverage platform contribution.
Background
Tilray’s fiscal year ended May 31, 2026, with results framed around adjusted profitability, liquidity, and segment momentum (international medical cannabis, distribution, and beverage expansion via BrewDog).
Ticker impact
Tilray reported fiscal 2026 record revenue of $915.5M and adjusted EBITDA of $61.1M, plus fiscal 2027 adjusted EBITDA guidance of $68–$75M.
Moderately positive bias for TLRY on guidance credibility, with volatility risk due to net loss driven by non-cash charges.
The article provides fresh, decision-relevant financial results and explicit forward guidance, but lacks detail on cash conversion quality beyond a stated operating cash flow improvement.
Market effects
Supports read-across for international medical cannabis and adjacent beverage/hospitality consumer activations tied to cannabis brands.
Highlights Europe medical cannabis momentum, potentially reinforcing investor focus on EU cannabis distribution and brands.
Signals continued consolidation and platform-building in cannabis-adjacent consumer categories via acquisitions.
Counterpoint
Record revenue and EBITDA may not translate into sustainable earnings power if non-cash charges remain elevated and adjusted net income stays small.
Key entities
- companyTilray Brands, Inc.
Reported record fiscal 2026 revenue and adjusted EBITDA, provided fiscal 2027 adjusted EBITDA guidance, and highlighted liquidity and segment momentum.
